These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33849373)

  • 1. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019.
    Patterson BJ; Chen CC; McGuiness CB; Glasser LI; Sun K; Buck PO
    Hum Vaccin Immunother; 2021 Aug; 17(8):2482-2487. PubMed ID: 33849373
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
    Leung J; Gray EB; Anderson TC; Sharkey SM; Dooling K
    Vaccine; 2022 Nov; 40(50):7187-7190. PubMed ID: 36347721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
    Parikh R; Singer D; Chmielewski-Yee E; Dessart C
    Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
    Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
    Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Fix J; Vielot NA; Lund JL; Weber DJ; Smith JS; Hudgens MG; Becker-Dreps S
    Vaccine; 2023 Jan; 41(1):49-60. PubMed ID: 36396511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study.
    McGirr A; Bourgoin T; Wortzman M; Millson B; McNeil SA
    Vaccine; 2021 Jun; 39(25):3397-3403. PubMed ID: 34001346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients.
    George S; Regan J; Awan A; O'Connor M; Foster A; Raymond K; Gorfinkel I; McNeil SA
    Hum Vaccin Immunother; 2024 Dec; 20(1):2317595. PubMed ID: 38502342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis.
    Patterson BJ; Chen CC; McGuiness CB; Ma S; Glasser LI; Sun K; Buck PO
    J Am Pharm Assoc (2003); 2022; 62(2):526-536.e10. PubMed ID: 34893442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.
    Hentzien M; Bonnet F; Bernasconi E; Biver E; Braun DL; Munting A; Leuzinger K; Leleux O; Musardo S; Prendki V; Schmid P; Staehelin C; Stoeckle M; Walti CS; Wittkop L; Appay V; Didierlaurent AM; Calmy A
    BMC Infect Dis; 2024 Mar; 24(1):329. PubMed ID: 38504173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021.
    LaMori J; Feng X; Pericone CD; Mesa-Frias M; Sogbetun O; Kulczycki A
    Vaccine; 2022 Apr; 40(15):2266-2273. PubMed ID: 35292160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older.
    Ackerson B; Qian L; Sy LS; Bruxvoort K; Wu J; Luo Y; Diaz-Decaro J; Talarico C; Tseng HF
    Vaccine; 2021 Feb; 39(6):926-932. PubMed ID: 33441234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US.
    Leung J; Anderson TC; Dooling K; Xie F; Curtis JR
    Arthritis Rheumatol; 2022 Nov; 74(11):1833-1841. PubMed ID: 35666070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
    Dooling KL; Guo A; Patel M; Lee GM; Moore K; Belongia EA; Harpaz R
    MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(3):103-108. PubMed ID: 29370152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.
    Florea A; Sy L; Qian L; Ackerson B; Luo Y; Wu J; Cheng Y; Ku J; Vega Daily L; Takhar H; Song J; Chmielewski-Yee E; Spence O; Seifert H; Oraichi D; Tseng HF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327145. PubMed ID: 38488143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
    Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
    Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.